A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
== Role in amyloidogenesis == The alpha sheet has been proposed as a possible intermediate state in the conformational change in the formation of amyloid fibrils by peptides and proteins such as amyloid beta, poly-glutamine repeats, lysozyme, prion proteins, and transthyretin repeats, all of which are associated with protein misfolding disease. For example, amyloid beta is a major component of amyloid plaques in the brains of Alzheimer's disease patients, and polyglutamine repeats in the huntingtin protein are associated with Huntington's disease. These proteins undergo a conformational change from largely random coil or alpha helix structures to the highly ordered beta sheet structures found in amyloid fibrils. Most beta sheets in known proteins are "twisted" about 15° for optimal hydrogen bonding and steric packing; however, some evidence from electron crystallography suggests that at least some amyloid fibrils contain "flat" sheets with only 1–2.5° of twist. An alpha-sheet amyloid intermediate is suggested to explain some anomalous features of the amyloid fibrillization process, such as the evident amino acid sequence dependence of amyloidogenesis despite the belief that the amyloid fold is mainly stabilized by the protein backbone. Xu, using atomic force microscopy, has shown that formation of amyloid fibers is a two-step process in which proteins first aggregate into colloidal spheres of ≈20 nm diameter. The spheres then join together spontaneously to form linear chains, which evolve into mature amyloid fibers.
The report found of the 40.3 million in modern slavery, 15.4 million are in forced marriages and 24.9 million are in forced labor. The foundation defines contemporary slavery as "situations of exploitation that a person cannot refuse or leave because of threats, violence, coercion, abuse of power, or deception."
Gives aid to "Catholic Communications" which produces TV and radio programs explaining the Catholic faith to Catholics and non-Catholics alike; annual pilgrimages to shrines; prayer card distributions; conducts picnics, bus trips, socials, etc.
Sources: en.wikipedia.org
Obstructed hernia: is one in which the lumen of the herniated part of the intestine is obstructed. Strangulated hernia: is one in which the blood supply of the hernia contents is cut off, thus leading to ischemia. The lumen of the intestine may be patent or not.
Although benzodiazepines are much safer in overdose than their predecessors, the barbiturates, they can still cause problems in overdose. Taken alone, they rarely cause severe complications in overdose; statistics in England showed that benzodiazepines were responsible for 3.8% of all deaths by poisoning from a single drug. However, combining these drugs with alcohol, opiates or tricyclic antidepressants markedly raises the toxicity. The elderly are more sensitive to the side effects of benzodiazepines, and poisoning may even occur from their long-term use. The various benzodiazepines differ in their toxicity; temazepam appears most toxic in overdose and when used with other drugs. The symptoms of a benzodiazepine overdose may include; drowsiness, slurred speech, nystagmus, hypotension, ataxia, coma, respiratory depression, and cardiorespiratory arrest. A reversal agent for benzodiazepines exists, flumazenil (Anexate), itself belonging to the chemical class of benzodiazepines. Its use as an antidote is not routinely recommended because of the high risk of resedation and seizures. In a double-blind, placebo-controlled trial of 326 people, 4 people had serious adverse events and 61% became resedated following the use of flumazenil. Numerous contraindications to its use exist. It is contraindicated in people with a history of long-term use of benzodiazepines, those having ingested a substance that lowers the seizure threshold or may cause an arrhythmia, and in those with abnormal vital signs.
== External links == "MMR (Measles, Mumps, & Rubella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. "MMRV (Measles, Mumps, Rubella & Varicella) Vaccine Information Statement". U.S. Centers for Disease Control and Prevention (CDC). 22 October 2019. Measles Vaccine at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
The maximum absorption of light is near 670 nm. The specifics of absorption depend on several factors, including protonation, adsorption to other materials, and metachromasy – the formation of dimers and higher-order aggregates depending on concentration and other interactions:
=== Cell Selection & Expansion === IBA has developed an affinity chromatography system for non-magnetic isolation of peripheral blood mononuclear cells, T cells, B cells and other cells of interest. This technology is known as Fab-TACS (Traceless Affinity Cell Selection) and is based on Strep-tagged Fab fragments, which reversibly capture and release the target cells. This delivers label-free, non-activated cells suitable for immunologic or cell biological assays. The technology can be used with manual gravity flow columns as well as with the automated cell selection device FABian. Isolated and purified cells are being deployed for basic research as well as diagnostic applications. The Streptamers for cell expansion enable the controlled stimulation of T cells. They consist of non-magnetic soluble protein complexes generated by multimerization of αCD3- and αCD28 Fab-Streps with a Strep-Tactin multimer. The reversible reagents can be easily removed from the cells by the addition of biotin. This allows to regulate the extent of stimulation precisely and to study functional and label-free activated T cells.
== Measurement techniques == GDGTs are identified via organic geochemical analysis as the polar head groups of the membrane lipids. High-precision liquid chromatography mass spectrometry (HPLC-MS) is the primary means by which GDGTs are analyzed due to this method's tolerance for high temperatures.
Keuning S, Janssen DB, Witholt B (1985). "Purification and characterization of hydrolytic haloalkane dehalogenase from Xanthobacter autotrophicus GJ10". J. Bacteriol. 163 (2): 635–9. doi:10.1128/JB.163.2.635-639.1985. PMC 219169. PMID 4019411. Scholtz R, Leisinger T, Suter F, Cook AM (1987). "Characterization of 1-chlorohexane halidohydrolase, a dehalogenase of wide substrate range from an Arthrobacter sp". J. Bacteriol. 169 (11): 5016–21. doi:10.1128/jb.169.11.5016-5021.1987. PMC 213902. PMID 3667524. Yokota T, Omori T, Kodama T (1987). "Purification and properties of haloalkane dehalogenase from Corynebacterium sp. strain m15-3". J. Bacteriol. 169 (9): 4049–54. doi:10.1128/jb.169.9.4049-4054.1987. PMC 213707. PMID 3624201. Poelarends GJ, van Hylckama Vlieg JE, Marchesi JR, Freitas Dos Santos LM, Janssen DB (1999). "Degradation of 1,2-dibromoethane by Mycobacterium sp. strain GP1". J. Bacteriol. 181 (7): 2050–8. doi:10.1128/JB.181.7.2050-2058.1999. PMC 93616. PMID 10094681. Poelarends GJ, Wilkens M, Larkin MJ, van Elsas JD, Janssen DB (1999). "Degradation of 1,3-dichloropropene by pseudomonas cichorii 170". Appl. Environ. Microbiol. 64 (8): 2931–6. doi:10.1128/AEM.64.8.2931-2936.1998. PMC 106795. PMID 9687453. Nagata Y, Miyauchi K, Damborsky J, Manova K, Ansorgova A, Takagi M (1997). "Purification and characterization of a haloalkane dehalogenase of a new substrate class from a gamma-hexachlorocyclohexane-degrading bacterium, Sphingomonas paucimobilis UT26". Appl. Environ. Microbiol. 63 (9): 3707–10. Bibcode:1997ApEnM..63.3707N. doi:10.1128/AEM.63.9.3707-3710.1997.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.